Issuer Client News

News & Events

Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa Yañez

Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa Yañez

DURHAM, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- It is with deep sadness that Aerami Therapeutics (“Aerami”) today announces that our dear friend, fierce patient advocate, dedicated mentor, and CEO, Lisa Yañez suddenly passed away on Tuesday, May 2, 2023. The entire Aerami community mourns the loss of Lisa and extends our deepest sympathies to her family during this difficult time. Lisa possessed limitless empathy, intellect, bravery, and compassion. Lisa’s career, fueled by her endless curiosity and passion for helping others, was magnificent, but most important to her was her family, whom she loved dearly. Our thoughts are with Lisa’s family and her extensive network of friends and colleagues.

Effective immediately, Anne Whitaker, Executive Chairwoman of the Board of Directors, will step in to lead Aerami and ensure all operations move forward as planned. Ms. Whitaker has a track record of more than 30 years of extensive leadership and industry commercialization experience in pharmaceuticals, biotech, consumer products, and medical devices. She has held leadership positions at Aerami since 2018, first as CEO overseeing the in-license and early development of the company’s AER-901 (inhaled imatinib) program, and then as Chairwoman of the Board of Directors since 2020.

Ms. Whitaker issued the following statement on behalf of the Aerami community: “We and everyone who knew Lisa Yañez have suffered a major loss with her passing. Lisa was a passionate, authentic leader who worked shoulder to shoulder with her colleagues, always focused on bringing solutions to help people live longer and better lives. She was a shining star in our healthcare community, and I feel very privileged to have had the opportunity to call her a colleague and a friend. I am confident that by working closely with the experienced and committed Aerami leadership team, we will honor Lisa's legacy by executing on our pulmonary hypertension clinical programs and maintaining our focus on improving the lives of the patients we serve.”

About Aerami Therapeutics

Aerami is a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary conditions. Aerami’s mission-drive approach to product development seeks to help patients live longer and live better by combining precision medicines and advanced administration platforms to support ease-of-use and quality-of-life.

Aerami Media Contact:
Joshua Ziel, PhD
VP, Chief of Staff

Aerami Investor Contact:
Jeremy Feffer
LifeSci Advisors

Primary Logo

Source: Aerami Therapeutics Inc

Brokerage and investment advisory products and services, are offered through Aegis Capital Corp, a member of FINRA and SIPC. Insurance products are made available through, ACC General Agency, a licensed insurance agency. For those persons inquiring from states where a specific associate is not currently securities and/or insurance licensed, the associate will not transact business in that state or provide follow-up individual responses, until after the associate obtains the appropriate registration in the applicable state.

The information provided should not be relied upon in isolation for the purpose of making an investment decision. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. Prior to making any investment or financial decision, an investor should seek advice from a financial, legal, tax and other professional that consider all of the particular facts and circumstances of an investor's situation. The opinions expressed and material provided are for information purposes only and is not an offer, recommendation, or solicitation of any product, strategy or transaction. Any views, strategies or products discussed may not be appropriate or suitable for all individuals and are subject to risks.

Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

Check the background of your financial professional on FINRA's BrokerCheck

Form CRS and General Disclosures

Aegis Risk Disclosures